The 2-year STEP 5 study discussed here aimed to assess the sustained impact of weekly subcutaneous semaglutide 2.4 mg, in conjunction with behavioral interventions, on body weight and cardiometabolic risks among non-diabetic adults grappling with obesity (BMI 30 kg m2) or overweight (BMI 27 kg m2 with at least one related comorbidity)
Limitations of the study should be considered
Authors contributions Conception of the consensus statement: ADO, LJO, JIMA, BJS, DLH Data extraction: LJO, AS, JMIA, KDK, ES, CRFR, RC Interpretation of data: ADO, LJO, BJS, AS, JMIA, KDK, ES, CRFR, RC, MDHA, CEM, MC, RM, GEU, DLH Writing the manuscript: ADO, LJO, AS, JMIA, MDHA, KDK, ES, CRFR, RC Revising the manuscript for important intellectual content: ADO, BJS, MC, RM, GEU, DLH Declarations of interest GEU receives grant support from Novo Nordisk, Merck, Insulcloud, Dexcom, Abbott, AstraZeneca, and Bayer
[5] Topical GHK-Cu is generally considered well tolerated, yet therapy should be avoided in individuals with a known hypersensitivity to copper peptides or any vehicle component
